UNSPSC 51281683: Porfiromycin

This classification denotes a mitomycin antibiotic with the molecular formula C16H20N4O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H1WK901OA6, chemically known as 6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-1,5-dimethylazirino(2,3:3,4)pyrrolo(1,2-a)indole-4,7-dione carbamate (ester) but more generally known as porfiromycin, which bears US NIH Compound Identifier 13116. European Medicines Agency schedules Porfiromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09980MIG.

The term PORFIROMYCIN is an International Non-Proprietary Name. PORFIROMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O(C12N(CC3N(C13)C)C1=C(C2COC(=O)N)C(=O)C(=C(C1=O)C)N)C.

UNSPSC 51281683 Porfiromycin, a Commodity code, covers pharmaceutical products procured by state and local health agencies and departments. The code nominally refers to a specific antibiotic; however, recent state and local solicitations tagged under this code show minimal activity directly aligned with porfiromycin procurement itself. Instead, activity centers on broader pharmaceutical warehouse supply arrangements and public-health pharmaceutical purchases through cooperative and piggyback contracts. State and local buyers accessing pharmaceutical inventory through these mechanisms include health departments, county health systems, and public-health authorities. Issuing bodies use cooperative purchasing vehicles such as MMCAP Infuse consortium contracts to aggregate demand and leverage established vendor relationships for drug procurement, reducing transaction costs and standardizing supply chains.

Recent activity appears concentrated in Florida and Illinois. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets on a 12-month term with two renewal options. Seminole County, Florida issued an IFB in June 2026 for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries and a two-year initial term plus one-year renewal option. Neither opportunity directly solicits porfiromycin. The code shows limited recent direct demand signal for the porfiromycin product line itself; activity under this UNSPSC classification reflects broader pharmaceutical sourcing through established cooperative and county health procurement channels rather than specific porfiromycin demand.